89 Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo
Zr immuno-PET continues to be assessed in numerous clinical trials. This report evaluates the use of Zr-chloride in the radiolabeling of monoclonal antibodies conjugated with desferrioxamine B (DFO), describes its effects on radiopharmaceutical reactivity toward antigen, and offers guidance on how t...
Gespeichert in:
Veröffentlicht in: | Journal of Nuclear Medicine 2019-05, Vol.60 (5), p.696-701 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Zr immuno-PET continues to be assessed in numerous clinical trials. This report evaluates the use of
Zr-chloride in the radiolabeling of monoclonal antibodies conjugated with desferrioxamine B (DFO), describes its effects on radiopharmaceutical reactivity toward antigen, and offers guidance on how to ensure long-term stability and purity.
Zr-DFO-trastuzumab and
Zr-DFO-cetuximab were prepared using
ZrCl
The stability of each was evaluated for 7 d in 20 mM histidine/240 mM sucrose buffer, 0.25 M sodium acetate (NaOAc) buffer containing 5 mg·mL
-acetyl-l-cysteine (NAC), or 0.25 M NaOAc containing 5 mg·mL
l-methionine (L-MET). To assess antigen reactivity,
Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer.
Using
ZrCl
,
Zr-DFO-trastuzumab and
Zr-DFO-cetuximab were prepared with increased specific activity and retained purities of 95% after 3 d when formulated in NaOAc buffer containing L-MET. Based on Lindmo analysis and small-animal PET/CT imaging,
Zr-DFO-trastuzumab remained reactive toward antigen after being prepared with
ZrCl
ZrCl
facilitated the radiosynthesis of
Zr immuno-PET agents with increased specific activity. L-MET enhanced long-term solution stability better than all other formulations examined, and
Zr-DFO-trastuzumab remained reactive toward antigen. Although further evaluation is necessary, these initial results suggest that
ZrCl
may be useful in immuno-PET radiochemistry as radiolabeled monoclonal antibodies are increasingly integrated into precision medicine strategies. |
---|---|
ISSN: | 0161-5505 1535-5667 2159-662X |
DOI: | 10.2967/jnumed.118.216457 |